Warfarin

Generic Name: Warfarin

Brand Names: Coumadin, Jantoven

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₆O_₄

CAS Number: 81-81-2

Unique Ingredient Identifier: 5Q7ZVV76EI

Background: Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...

Indication: Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...

Associated Conditions: Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

Associated Therapies: -

Clinical Trials

Rivaroxaban vs. Warfarin in CVT Treatment

Phase 3

Completed

Conditions: Cerebral Vein Thrombosis

Interventions: Drug: Warfarin
Drug: Rivaroxaban

First Posted Date: 2020-09-29

Last Posted Date: 2023-02-16

Lead Sponsor: Damascus University

Target Recruit Count: 71

Registration Number: NCT04569279

Locations: 🇸🇾
Damascus University, Damascus, Damascus Governorate, Syrian Arab Republic

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Warfarin

First Posted Date: 2020-08-11

Last Posted Date: 2022-06-15

Lead Sponsor: Bayer

Target Recruit Count: 116049

Registration Number: NCT04509193

Locations: 🇺🇸
US Optum De-Identified EHR data, Whippany, New Jersey, United States

Gene-guided Warfarin for Anticoagulation Therapy

Not Applicable

Withdrawn

Conditions: Stroke

Interventions: Device: Gene detection (CYP2C9*3, VKORC1)
Drug: Warfarin Sodium

First Posted Date: 2020-07-23

Last Posted Date: 2021-08-25

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Registration Number: NCT04482842

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Completed

Conditions: Uterine Hemorrhage

Interventions: Drug: Direct oral anticoagulant (DOACs)
Drug: Warfarin

First Posted Date: 2020-05-19

Last Posted Date: 2020-06-11

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 961985

Registration Number: NCT04394234

Locations: 🇺🇸
Janssen R&D, Titusville, New Jersey, United States

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto)
Drug: Warfarin
Drug: Apixaban
Drug: Dabigatran

First Posted Date: 2020-01-31

Last Posted Date: 2024-08-01

Lead Sponsor: Bayer

Target Recruit Count: 134897

Registration Number: NCT04249401

Locations: 🇸🇪
Many locations, Multiple Locations, Sweden

The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Withdrawn

Conditions: Atrial Fibrillation

Interventions: Drug: apixaban
Drug: warfarin

First Posted Date: 2019-12-13

Last Posted Date: 2020-06-01

Lead Sponsor: Pfizer

Registration Number: NCT04198844

Locations: 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Phase 3

Terminated

Conditions: Aortic Valve Disease
Aortic Valve Stenosis
Aortic Valve Failure

Interventions: Drug: Warfarin
Drug: Apixaban 5 MG
Drug: Apixaban 2.5 MG
Device: On-X Aortic Mechanical Valve

First Posted Date: 2019-10-29

Last Posted Date: 2024-03-20

Lead Sponsor: Artivion Inc.

Target Recruit Count: 863

Registration Number: NCT04142658

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Piedmont Atlanta Hospital, Atlanta, Georgia, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 59 locations

Safety and Efficacy of Edoxaban in Thoracoscopic Ablation

Not Applicable

Completed

Conditions: Atrial Fibrillation
Anticoagulants and Bleeding Disorders

Interventions: Drug: Warfarin
Drug: Edoxaban

First Posted Date: 2019-10-10

Last Posted Date: 2020-08-03

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 60

Registration Number: NCT04121767

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

AntiCoagulants and COGnition

Phase 4

Conditions: Nonvalvular Atrial Fibrillation

Interventions: Drug: Rivaroxaban 20 MG
Drug: Warfarin

First Posted Date: 2019-08-29

Last Posted Date: 2022-07-27

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 48

Registration Number: NCT04073316

Locations: 🇫🇷
Angers University Hospital, Angers, France

Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Phase 3

Recruiting

Conditions: May-Thurner Syndrome

Interventions: Drug: Rivaroxaban
Drug: Warfarin
Drug: Nadroparin

First Posted Date: 2019-08-26

Last Posted Date: 2024-04-18

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 224

Registration Number: NCT04067505

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Shanghai 5th People's Hospital, Shanghai, Shanghai, China
🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy